290 related articles for article (PubMed ID: 32154941)
1. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
[TBL] [Abstract][Full Text] [Related]
2. Blocking the road to de-differentiation: HNF1A/KDM6A complex safeguards epithelial integrity in pancreatic cancer.
Bärthel S; Schneider G; Saur D
EMBO J; 2020 May; 39(9):e104759. PubMed ID: 32236961
[TBL] [Abstract][Full Text] [Related]
3. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
5. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
[TBL] [Abstract][Full Text] [Related]
7. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.
Martinelli P; Madriles F; Cañamero M; Pau EC; Pozo ND; Guerra C; Real FX
Gut; 2016 Mar; 65(3):476-86. PubMed ID: 25596178
[TBL] [Abstract][Full Text] [Related]
8. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
9. KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway.
Yi Z; Wei S; Jin L; Jeyarajan S; Yang J; Gu Y; Kim HS; Schechter S; Lu S; Paulsen MT; Bedi K; Narayanan IV; Ljungman M; Crawford HC; Pasca di Magliano M; Ge K; Dou Y; Shi J
Cell Mol Gastroenterol Hepatol; 2022; 13(2):643-667. PubMed ID: 34583087
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of pancreatic cancer reveals a tumor suppressor function for HNF1A.
Hoskins JW; Jia J; Flandez M; Parikh H; Xiao W; Collins I; Emmanuel MA; Ibrahim A; Powell J; Zhang L; Malats N; Bamlet WR; Petersen GM; Real FX; Amundadottir LT
Carcinogenesis; 2014 Dec; 35(12):2670-8. PubMed ID: 25233928
[TBL] [Abstract][Full Text] [Related]
11. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
[TBL] [Abstract][Full Text] [Related]
12. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
13. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
14. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
15. Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex.
Jamali M; Barar E; Shi J
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791111
[TBL] [Abstract][Full Text] [Related]
16. ANGPTL4 accelerates KRAS
Yan HH; Jung KH; Lee JE; Son MK; Fang Z; Park JH; Kim SJ; Kim JY; Lim JH; Hong SS
Cancer Lett; 2021 Oct; 519():185-198. PubMed ID: 34311032
[TBL] [Abstract][Full Text] [Related]
17. KDM6A Loss Recruits Tumor-Associated Neutrophils and Promotes Neutrophil Extracellular Trap Formation in Pancreatic Cancer.
Yang J; Jin L; Kim HS; Tian F; Yi Z; Bedi K; Ljungman M; Pasca di Magliano M; Crawford H; Shi J
Cancer Res; 2022 Nov; 82(22):4247-4260. PubMed ID: 36306422
[TBL] [Abstract][Full Text] [Related]
18. The Loss of ATRX Increases Susceptibility to Pancreatic Injury and Oncogenic KRAS in Female But Not Male Mice.
Young CC; Baker RM; Howlett CJ; Hryciw T; Herman JE; Higgs D; Gibbons R; Crawford H; Brown A; Pin CL
Cell Mol Gastroenterol Hepatol; 2019; 7(1):93-113. PubMed ID: 30510993
[TBL] [Abstract][Full Text] [Related]
19. GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant
Shen J; Ha DP; Zhu G; Rangel DF; Kobielak A; Gill PS; Groshen S; Dubeau L; Lee AS
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4020-E4029. PubMed ID: 28461470
[TBL] [Abstract][Full Text] [Related]
20. Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.
Jakubison BL; Schweickert PG; Moser SE; Yang Y; Gao H; Scully K; Itkin-Ansari P; Liu Y; Konieczny SF
Mol Oncol; 2018 Jun; 12(7):1104-1124. PubMed ID: 29719936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
